The rights include ATN-103 and PF-05230905 products.
Ablynx will also acquire Pfizer intellectual property and know-how with regarding to the anti-TNF-alpha programmes and will have access to Pfizer’s current trial supplies of ATN-103 and PF-05230905, assay methods and manufacturing processes.
Pfizer will receive milestone payments valued at $50 million and royalty on sales from Ablynx following the regulatory approval of the first anti-TNF-alpha Nanobody.
In 2006 Ablynx granted Wyeth (acquired by Pfizer in 2009) exclusive worldwide rights to Nanobodies targeting TNF-alpha under a research collaboration and license agreement.